Heng Fai Holdings

Heng Fai Holdings is a private investment holding company and business incubator led by financier Chan Heng Fai, with a significant focus on the life sciences and longevity sectors. The company operates primarily through its publicly listed subsidiaries, Alset International Limited and Alset Inc., which manage a diverse portfolio of biohealth interests. A key component of its biotechnology strategy is a strategic partnership with American Gene Technologies (AGT) to develop AGT103-T, a gene therapy aimed at providing a functional cure for HIV. Additionally, the group is active in the longevity space through its Alset BioHealth division, which commercializes NMN-based supplements and researches anti-aging interventions. Heng Fai Holdings also maintains significant interests in oncology through investments in companies like Bio-Path Holdings, which is developing antisense therapeutics for leukemia. The firm leverages its global network to identify and scale medical innovations, transitioning them from clinical research to market-ready healthcare solutions.